Show simple item record

dc.contributor.authorDrummond, J
dc.contributor.authorRoncaroli, F
dc.contributor.authorGrossman, AB
dc.contributor.authorKorbonits, M
dc.date.accessioned2020-04-29T15:42:02Z
dc.date.available2018-07-12
dc.date.available2020-04-29T15:42:02Z
dc.date.issued2018-07-17
dc.identifier.citationDrummond, J., et al. (2018). "Clinical and Pathological Aspects of Silent Pituitary Adenomas." The Journal of Clinical Endocrinology & Metabolism 104(7): 2473-2489.en_US
dc.identifier.issn0021-972X
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/63834
dc.description.abstractCONTEXT: Silent pituitary adenomas are anterior pituitary tumors with hormone synthesis but without signs or symptoms of hormone hypersecretion. They have been increasingly recognized and represent challenging diagnostic issues. EVIDENCE ACQUISITION: A comprehensive literature search was performed using MEDLINE and EMBASE databases from January 2000 to March 2018 with the following key words: (i) pituitary adenoma/tumor and nonfunctioning; or (ii) pituitary adenoma/tumor and silent. All titles and abstracts of the retrieved articles were reviewed, and recent advances in the field of silent pituitary adenomas were summarized. EVIDENCE SYNTHESIS: The clinical and biochemical picture of pituitary adenomas reflects a continuum between functional and silent adenomas. Although some adenomas are truly silent, others will show some evidence of biochemical hypersecretion or could have subtle clinical signs and, therefore, can be referred to as clinically silent or "whispering" adenomas. Silent tumors seem to be more aggressive than their secreting counterparts, with a greater recurrence rate. Transcription factors for pituitary cell lineages have been introduced into the 2017 World Health Organization guidelines: steroidogenic factor 1 staining for gonadotroph lineage; PIT1 (pituitary-specific positive transcription factor 1) for growth hormone, prolactin, and TSH lineage, and TPIT for the corticotroph lineage. Prospective studies applying these criteria will establish the value of the new classification. CONCLUSIONS: A concise review of the clinical and pathological aspects of silent pituitary adenomas was conducted in view of the new World Health Organization classification of pituitary adenomas. New classifications, novel prognostics markers, and emerging imaging and therapeutic approaches need to be evaluated to better serve this unique group of patients.en_US
dc.description.sponsorshipJ.D. was supported by a grant from the Brazilian Federal Agency for Support and Evaluation of Postgraduate Education (CAPES). The studies of M.K. on pituitary adenomas were supported by the Medical Research Council, Rosetrees Trust, and Wellcome Trust.en_US
dc.format.extent2473 - 2489
dc.languageeng
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofJ Clin Endocrinol Metab
dc.rightsCC-BY
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectSilent pituitary adenomasen_US
dc.subjectpituitary neuroendocrine tumorsen_US
dc.titleClinical and Pathological Aspects of Silent Pituitary Adenomas.en_US
dc.typeArticleen_US
dc.rights.holder2018. The authors
dc.identifier.doi10.1210/jc.2018-00688
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/30020466en_US
pubs.issue7en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume104en_US
dcterms.dateAccepted2018-07-12
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC-BY
Except where otherwise noted, this item's license is described as CC-BY